317335-27-6

Basic information

• Product Name: N-methoxy-N,5-dimethyl-2-Pyrazinecarboxamide
• Synonyms: N-methoxy-N,5-dimethyl-2-Pyrazinecarboxamide;N-Methoxy-N,5-dimethylpyrazine-2-carboxamide
• CAS NO: 317335-27-6
• Molecular Formula: C₈H₁₁N₃O₂
• Molecular Weight: 181.2
• Mol File: 317335-27-6.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 346.2±42.0 °C(Predicted)
• Appearance: /
• Density: 1.178±0.06 g/cm3(Predicted)
• PKA: 0.54±0.10(Predicted)
• CAS DataBase Reference: N-methoxy-N,5-dimethyl-2-Pyrazinecarboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-methoxy-N,5-dimethyl-2-Pyrazinecarboxamide(317335-27-6)
• EPA Substance Registry System: N-methoxy-N,5-dimethyl-2-Pyrazinecarboxamide(317335-27-6)

Safety Data

• Hazardous Substances Data: 317335-27-6(Hazardous Substances Data)

Upstream product

• 5521-55-1 2-methylpyrazin-5-carboxylic acid 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 

Downstream Products

• 317334-69-3 (3-benzyl-5-bromophenyl)(5-methylpyrazin-2-yl)ketone 
• 22047-27-4 1-(5-methylpyrazin-2-yl)ethanone 
• 1017598-63-8 (3,4-difluorophenyl)(5-methylpyrazin-2-yl)methanone 
• 500370-22-9 4-fluorophenyl-5-methylpyrazin-2-ylmethanone 

Relevant articles and documents

DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR

[Problems] To provide an antagonist of a melanin-concentrating hormone receptor, which is useful as a medicine for a central nervous system disease, a cardiovascular disease or a metabolic disease. [Means for Solving Problems] The antagonist comprises, as an active ingredient, a compound represented by the formula (I) wherein R1a and R1b independently represent a hydrogen atom or a C1-6 alkyl group; R2a, R2b, R3a and R3b independently represent a hydrogen atom, a C1-6 alkyl group, or the like; Y represents H or —OH; Z represents —OR8, or the like; R8 represents a hydrogen atom, a C1-6 alkyl group which may have a substituent, or the like; R9a and R9b independently represent a hydrogen atom, a C1-6 alkyl group, or the like; Ar1 represents an aromatic carbon ring group, or an aromatic heteroring group; Ar2 represents a group produced by removing two hydrogen atoms from an aromatic carbon ring, or the like; and the ring group A represents an unsaturated heteroring group.

PYRAZOLE DERIVATIVES

A compound represented by formula (I): (wherein Ar1 represents a phenyl group which may have 1 to 3 substituents, or a non-substituted 5- or 6-membered aromatic heterocyclic group; Ar2 represents (i) a non-substituted phenyl group, (ii) a phenyl group which has been substituted by a lower alkyl group having 1 to 3 groups or atoms selected from among a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom, or (iii) a 5- or 6-membered nitrogen-containing aromatic heterocyclic group which has been substituted by 1 to 3 groups or atoms selected from among a lower alkyl group, a lower alkynyl group, a lower alkanoyl group, a carbamoyl group, a cyano group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom; and X represents a group represented by formula (II): (wherein the ring structure represents a 4- to 7-membered heterocyclic group which may have, in addition to the nitrogen atom shown in formula (II), one heteroatom selected from among nitrogen, oxygen, and sulfur, and which may be substituted by 1 to 4 groups or atoms selected from among a lower alkyl group, a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, an oxo group, a lower alkanoyl group, a lower alkylsulfonyl group, and a halogen atom)), a salt thereof, a solvate of the compound or the salt, and a drug.

AMIDOPYRAZOLE DERIVATIVE

A platelet coagulation inhibitor which inhibits neither COX-1 nor COX-2 is provided. The inhibitor is a compound represented by general formula (I): wherein Ar1 and Ar2 independently represent a 5- or 6-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents, or a phenyl group optionally substituted with 1 to 3 substituents; R1 represents a lower acyl group, carboxyl group, a lower alkoxycarbonyl group, a lower alkoxy group, a lower alkyl group optionally substituted with 1 or 2 substituents, a carbamoyl group optionally substituted with 1 or 2 substituents, an oxamoyl group optionally substituted with 1 or 2 substituents, an amino group optionally substituted with 1 or 2 substituents, a 4- to 7-membered alicyclic heterocyclic group optionally substituted with 1 or 2 substituents, a phenyl group optionally substituted with 1 to 3 substituents, or a 5- or 6-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents; and R2 represents hydrogen atom, a halogeno group, or the like.